anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
INTRODUCTION: There is a proven role for hepcidin and the composition of gut microbiota and its derivatives in the pathophysiology of liver fibrosis.
AREA COVERED: This review focuses on the literature search regarding the effect of hepcidin and gut microbiota on regulating liver physiology. We presented the regulating mechanisms of hepcidin expression and discussed the possible interaction between gut microbiota and hepcidin regulation. Furthermore, we investigated the importance of the hepcidin gene in biological processes and bacterial interactions using bioinformatics analysis.
EXPERT OPINION: One of the main features of liver fibrosis is iron accumulation in hepatic cells, including hepatocytes. This accumulation can induce an oxidative stress response, inflammation, and activation of hepatic stellate cells. Hepcidin is a crucial regulator of iron by targeting ferroportin expressed on hepatocytes, macrophages, and enterocytes. Various stimuli, such as iron load and inflammatory signals, control hepcidin regulation. Furthermore, a bidirectional relationship exists between iron and the composition and metabolic activity of gut microbiota. We explored the potential of gut microbiota to influence hepcidin expression and potentially manage liver fibrosis, as the regulation of iron metabolism plays a crucial role in this context.
<P>PROBLEM TO BE SOLVED: To fabricate the 3-D networks of nanofibers by mixing a growth factor solution with aqueous solution of peptide amphiphile as an injectable carrier for controlled release of growth factors and used it for feasibility of prevascularization by the growth factor release from the 3-D networks of nanofibers in improving efficiency of ES cells transplantation in an ischemic cardiomyopathy model.  <P>SOLUTION: We hypothesized that a novel approach to promote ES cells differentiation and vascularization would be to create injectable three dimensional (3-D) scaffolds containing growth factor that enhance the sustained release of the growth factor and induce angiogenesis. Then we completed the method. This method regenerates cardiac tissue by combination of stem cells, growth factor and peptide-amphiphile. As the above growth factor, we can preferably use basic fibroblast growth factor (bFGF).  <P>COPYRIGHT: (C)2009,JPO&INPIT
The invention relates to pain-relieving paste suitable for various rheumatisms, gouts and traumatic injuries. The pain-relieving paste is characterized by being prepared from bulk pharmaceuticals according to weight parts in a specified range. A preparation method of the paste provided by the invention comprises the following steps: decocting raw materials except a paste substrate and borneol with water in an amount which is 6 to 8 times the total quantity of the raw materials by adopting a conventional method, sieving, airing and smashing decoction dregs with a No. 5 sieve, grinding the decoction dregs into powder, and drying; filtering decocted liquid to obtain filtrate, combining the filtrate and distilled medicinal liquor, concentrating the mixture into pasty thick liquid which is 1.33 in specific weight at the temperature of 80 DEG C, uniformly mixing powder prepared from decoction dregs left after filtering of the thick liquid and the medicinal liquor, the ground borneol and the paste substrate, and uniformly spreading on a cut cloth block. A use method of the pain-relieving paste comprises the following steps: cleaning an affected part; applying a patch of 25g to the affected part every time for 1 to 2 days, wherein diathermy can be taken as an assistant measure. Compared with the prior art, the pain-relieving paste has the advantages of suitability for various rheumatisms, gouts and traumatic injuries, quick response and convenience in use.
The individuals participated in an intervention program which consisted of four individual sessions a week, with 30 minutes. In these sessions, the instructions about feeding were performed. The individuals received all the instructions on a written document. In the sessions, it was verified doubts about the guidelines and treatment adherence. In this group, it was not applied the Chin-down postural maneuver.
A 28-year-old male presented with a sudden, transient visual impairment in the right eye. Brain MRI revealed no obvious ischemic lesions, and he was diagnosed with amaurosis fugax. Physical examination revealed characteristic features of Marfan syndrome, along with a family history of tall stature and valvular heart disease. Further investigation revealed: 1) an ascending aortic aneurysm, 2) a bicuspid aortic valve with fenestration and regurgitation, and 3) a mitral valve prolapse with regurgitation. Genetic testing identified a heterozygous variant c.6905G>A of FBN1, confirming the diagnosis of Marfan syndrome. Bentall operation and mitral valve replacement were performed, resulting in a favorable outcome. Pathological examination showed extensive myxomatous degeneration with thickening of the aortic and mitral valves, suggesting a potential source of embolism.
Described herein are beverages that can enhance sexual performance in both men and women. For example, the beverages are useful in promoting endurance and stamina and in increasing sexual desire as well as blood flow to the genital region. Components of the beverages are also associated with a reduced risk of cardiovascular disease in subjects who consume the beverages. The beverages are composed of pomegranate juice, ginseng, maca root, and  L -arginine or a pharmaceutically acceptable salt thereof. The beverages may additionally include B complex vitamins including folic acid, as well as Tongkat Ali and/or damiana leaf. Vitamins, minerals, other nutrients, and other natural products can also be added to the beverages to provide additional health benefits.
In a pooled analysis of placebo-controlled hypertension studies with about 300 hypertensive patients per treatment group, doxazosin, at doses of 1 to 16 mg given once daily, lowered blood pressure at 24 hours by about 10/8 mmHg compared to placebo in the standing position and about 9/5 mmHg in the supine position. Peak blood pressure effects (1–6 hours) were larger by about 50–75% (i.e., trough values were about 55–70% of peak effect), with the larger peak-trough differences seen in systolic pressures. There was no apparent difference in the blood pressure response of Caucasians and blacks or of patients above and below age 65. In the same patient population, patients receiving doxazosin mesylate gained a mean of 0.6 kg compared to a mean loss of 0.1 kg for placebo patients.

TABLE 4 Mean Changes in Blood Pressure from Baseline to the Mean of the Final Efficacy Phase in Normotensives (Diastolic BP < 90 mmHg) in Two Double-blind, Placebo-controlled U.S. Studies with Doxazosin Mesylate 1 to 8 mg once daily.

*p ≤0.05 compared to placebo
In cardiac tissue engineering, myocardial surface patches and hydrogel intramyocardial injections represent the two primary hydrogel-based strategies for myocardial infarction (MI) treatment. However, the comparative effectiveness of these two treatments remains uncertain. Therefore, this study aimed to compare the effects of the two treatment modalities by designing a simple and reproducible hydrogel cross-linked with γ-PGA and 4-arm-PEG-SG. To improve mitochondrial damage in cardiomyocytes (CMs) during early MI, we incorporated the mitochondria-targeting antioxidant MitoQ into the hydrogel network. The hydrogel exhibited excellent biodegradability, biocompatibility, adhesion, and injectability in vitro. The hydrogel was utilized for rat MI treatment through both patch adhesion and intramyocardial injections. In vivo results demonstrated that the slow release of MitoQ peptide from the hydrogel hindered ROS production in CM, alleviated mitochondrial damage, and enhanced CM activity within 7 days, effectively inhibiting MI progression. Both hydrogel intramyocardial injections and patches exhibited positive therapeutic effects, with intramyocardial injections demonstrating superior efficacy in terms of cardiac function and structure in equivalent treatment cycles. In conclusion, we developed a MitoQ/hydrogel system that is easily prepared and can serve as both a myocardial patch and an intramyocardial injection for MI treatment, showing significant potential for clinical applications.
In 2020, acquired cystic disease-associated renal cell carcinomas (ACD-RCCs) were reported to harbor KMT2C and TSC2 variants: however, their carcinogenic implication has not yet been reported. This study aimed to explore the variant features of KMT2C and TSC2 in ACD-RCC and their implication in ACD-RCC tumorigenesis. Eleven ACD-RCCs, 10 ACD-RCC-like cysts, and 18 background kidneys were retrieved. The background kidneys consisted of atrophic thyroid follicle-like tubules. They included four with clustered cysts, two with eosinophilic changes, and one each with clear cell changes and sieve-like changes in the renal tubules. First, DNA-targeted sequencing of KMT2C and TSC2 whole exons was performed on eight ACD-RCC samples. Subsequently, a custom DNA panel was designed to include the recurrent KMT2C and TSC2 variants based on the sequencing results. Second, DNA-targeted sequencing was performed on the remaining samples using a custom panel targeting the recurrent variants. Additionally, immunohistochemistry was performed for KMTC, H3K4me1, H3K4me3, TSC2, and GPNMB on the ACD-RCCs. Six of the 11 ACD-RCC cases harbored KMT2C and TSC2 variants, including nine likely pathogenic variants. In contrast to ACD-RCC, 1 of the 9 ACD-RCC-like cysts harbored both variants. Immunohistochemical analysis did not support the loss of function in ACD-RCCs harboring KMT2C and TSC2 variants. KMT2C and TSC2 variant frequencies were higher in ACD-RCC than in other renal cell carcinomas. However, KMT2C and TSC2 are unlikely to be the primary drivers of ACD-RCC development.
The most effective method to prevent hepatitis B virus infection is to receive the vaccination of hepatitis b vaccine to get the protective antibody anti-HBs. Both the blood-derived hepatitis B vaccine and the recombinant hepatitis B vaccines have been proved to be effective and safe since the application in 1981 and 1989 respectively. Previous passive or active immunization testes indicated that the lowest effective level of anti-HBs for prevention of infection is 10mIU/ml. However there are still some recipients can't generate expected level of anti-HBs after the vaccinations. In adults, there are 5% to 10% recipients will failed to respond to routine administration of 10mcg recombinant hepatitis B vaccines, and those nonresponders are susceptible population even after the vaccinations. In this study, a recipient whose peak period (1 month after vaccination) levels of anti-HBs is lower than 10mIU/ml after finishing the vaccinations of 3 dose 10mcg hepatitis b vaccines is called nonresponders.

Nowadays, a lot tests are conducted on nonresponders to help them generate the protective antibody anti-HBs, including increase the antigen dosage of vaccines, increase the injections of vaccines, change the route of inoculation and the use of adjuvant. Unfortunately, these previous studies can not get coincident and persuasive outcomes due to the small sample size and poor representativeness. This study is plan to evaluate the immunogenicity and safety of 60mcg/30mcg recombinant hepatitis B vaccines in people aged 16 and older who failed to respond to routine administration of 10mcg recombinant hepatitis B vaccines and to provide the scientific evidences for the revaccination strategy in China.
The active control group consists a 16-week waiting period, where treatment as usual is allowed. In case of acute worsening/progression of the symptoms, consultations with the study physician are offered anytime. After the waiting period, the control group will be offered the same units as in the experimental group.
Patients receive pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days for up to 24 months in the absence of disease progression or unacceptable toxicity. Upon radiologic documentation of disease progression, patients may cross over to Group II.
Training will be performed using the Amadeo®. The computer-controlled device maintains participants' forearm in a secure position using Velcro straps. Each training session will include 30 minutes of active movements that can be divided into up to 3 bouts of 10 minutes depending on participant's fatigue. Training will take place up to 4 times per week for a total of 18 sessions over up to 7 weeks. Sessions will last approximately 60 minutes (including setup, training, and rest between each bout).
ELIGARD® is administered subcutaneously and provides continuous release of leuprolide acetate over a one-, three-, four-, or six-month treatment period (Table 1). The injection delivers the dose of leuprolide acetate incorporated in a polymer formulation. 

Table 1. ELIGARD® Recommended Dosing

As with other drugs administered by subcutaneous injection, the injection site should vary periodically. The specific injection location should be an area with sufficient soft or loose subcutaneous tissue. In clinical trials, the injections were administered in the upper- or mid-abdominal area. Avoid areas with brawny or fibrous subcutaneous tissue or locations that could be rubbed or compressed (i.e., with a belt or clothing waistband).
The present invention relates to the composition of nanometer SOD and milkvetch root or the extract of milkvetch root, and a preparation method of the composition. In 1 to 100000 active units of nanometer SOD, 1 to 50 g of nanometer milkvetch root or the extract of nanometer milkvetch root is contained, and the grain diameter is smaller than or equal to 10 to 80 nanometers. The combination application of the nanometer composition of the nanometer SOD and the milkvetch root or the extract of milkvetch root enhances the concentration and the effective components of the drug. The anti-oxidation activity is enhanced by more than 10 times, the skin and mucous membrane absorption rate reaches more than 98%, and the half-life is prolonged by more than two orders of magnitude. The composition of nanometer SOD and milkvetch root or the extract of milkvetch root can enter cells to directly clear free radicals, and has stronger anti-lipid peroxidation. The comprehensive drug effects are more thoroughly exerted and are much better than the drug effects of the traditional compound Chinese drugs. The composition of nanometer SOD and milkvetch root or the extract of milkvetch root is used for preventing and treating cold, treating pedo-bronchial asthma, chronic hepatitis b, chronic nephritis, viral myocarditis and peptic ulcer, and can also be used for the nervous system. The composition of nanometer SOD and milkvetch root or the extract of milkvetch root is suitable for athletes, emergent patients, and people with external wounds. The absorption speed is very high. The drug effect is 3 to 5 times higher than that of SOD and is 5 to 10 times higher than that of milkvetch root. The composition of nanometer SOD and milkvetch root or the extract of milkvetch root is contribution to the human medicine career.
Abducens nerve palsy caused by neurovascular conflicts is rare and requires further exploration. This study aimed to investigate the clinical features and surgical outcomes of abducens palsy caused by neurovascular conflict. Twenty-six patients with abducens palsy caused by neurovascular conflict were included in present study. The clinical data and treatment outcomes were retrospectively analyzed. Symptom improvement score was used to evaluate the changes in diplopia, which include five grades: complete remission, significant relief, partial relief, no improvement, and worsening of symptoms. Neurovascular conflict was determined in 26 patients (12 male and 14 female) with a mean age of 60.54 ± 13.55 years (range, 35 to 84 years). The mean duration of symptoms was 10.19 ± 11.30 months (range, 1 to 60 months). Ten patients underwent microvascular decompression (MVD) while 16 patients received observation and drug therapy. No fatal complications occurred in any patient. In the MVD group, 9 patients achieved remission of diplopia, while 1 patient showed no change in symptoms. In observation group, only 4 patients achieved symptom relief and 12 patients showed no improvement or worsened. The symptom improvement score of MVD group was significantly higher than that of observation group at last follow-up (3.50 ± 0.97 vs. 1.38 ± 0.95, P < 0.001). Neurovascular compression, although rare, should be considered as a possible underlying cause of isolated abducens nerve palsy. Microvascular decompression can be considered a treatment option based on the comprehensive preoperative evaluation. Patients with significant atrophy of the extraocular muscles are unsuitable for MVD surgery.
OBJECTIVES: To investigate the incidence rate, clinical characteristics across different age groups, antimicrobial susceptibility, and outcomes of Elizabethkingia meningoseptica (E. meningoseptica) infections.
METHODS: A retrospective analysis was carried out to include 66 cases with confirmed E. meningoseptica cultures from sterile samples between January 2014 and June 2022 at King Faisal Specialist Hospital and Research Centre in Riyadh, Saudi Arabia.
RESULTS: A total of 66 cases were identified, with an incidence rate of 0.3 per 1000 admissions. Most cases were hospital-acquired (80.3%), primarily in critical care areas. All patients had underlying diseases, with respiratory (40.9%) and cardiovascular (39.4%) diseases being the most common. Minocycline showed the highest susceptibility (96.0%), followed by trimethoprim/sulfamethoxazole (77.0%), whereas tobramycin and colistin were fully resistant. The in-hospital mortality rate was 34.8%, whereas the 28-day mortality rate was 22.7%. Clinical characteristics across age groups showed a higher prevalence of cardiovascular disease in pediatrics than in adults, whereas exposure to mechanical ventilation, immunosuppressive therapy, previous infection, anemia, and in-hospital mortality were reported more frequently in adults (p<0.05).
CONCLUSION: Our study provides valuable insights into E. meningoseptica infection in Saudi Arabia, emphasizing the importance of robust infection control measures. Incidence and mortality rates align with global trends. Variations in clinical characteristics across age groups highlight the importance of tailored treatments based on patient demographics and underlying comorbidities.
The second session will take place 3 days after the first one and will follow the same procedure as session 1. However, histamine will be applied instead of cowhage. The order of the two sessions will be randomized.
OBJECTIVE: Memory is one of the most sensitive markers of cognitive compromise in people with new-onset epilepsy. Nonetheless, around half of these cases score within the normal range on standard memory testing. Here we explore whether memory retention at a 1-week delay reveals otherwise undetected memory compromise in such individuals, and how it relates to subjective memory complaints and mood.
METHODS: Using a prospective design, 38 adults with new-onset epilepsy underwent baseline memory screening via telephone using an abbreviated Rey Auditory Verbal Learning Test (RAVLT). Psychological screening occurred via online questionnaires. One week later, without forewarning, participants completed three follow-up memory tasks. Of particular focus, we explored longer-term memory performances and forgetting trajectories in those individuals (n = 23) who demonstrated normal memory performances (scores >10th percentile) at baseline (30-min delay). Outcomes were compared to 32 healthy controls, matched for age, sex, and education.
RESULTS: As a group, people with epilepsy performed worse than controls on all memory measures, with 44 percent impaired at baseline testing. Of those unimpaired at baseline, the rate and volume of information loss over 1 week was significantly greater than for controls. Contextual memory performance at 1 week was also significantly poorer for people with epilepsy. At the individual level, the prevalence of impaired forgetting was not significantly different between patients and controls. Subjective memory complaints were not related to any objective tests but were strongly related to self-reported mood and anxiety symptoms.
SIGNIFICANCE: People with new-onset epilepsy show reduced memory at short and extended intervals. For those showing normal memory at baseline, information does appear to be forgotten more quickly than in healthy controls, though the effect is not large. The findings indicate that while extended delay memory testing is not essential in all new epilepsy cases, it could provide useful information for particular individuals.
PLAIN LANGUAGE STATEMENT: Memory problems are common in people with epilepsy shortly after seizure onset, however, many individuals still show normal memory performances on standard neuropsychological testing. Through testing memory at an extended timepoint (1 week), our study found that on average, these individuals showed a slightly quicker rate of forgetting over a 1-week period than people without a brain condition. Self-reported memory complaints in people with new epilepsy were unrelated to their actual memory skills on testing at short and long timepoints but were rather linked to lower mood and quality of life.
The present invention provides methods for designing a sequence for efficient short interference RNA molecules. In particular, the present invention defines a universal target for siRNA derived from a poly A sequence, optionally in conjunction with unique sequences for gene silencing and inhibition of viral replication in a eukaryotic host cell. The present invention further provides methods for the treatment and prevention of diseases and disorders by silencing a gene of a virus, an oncogene, genes encoding transcription factors and many other diseases related genes. The present invention describes antisense nucleic acids compositions comprising sequences complementary to a target nucleic acid. The antisense sequences are designed to hybridize to complementary nucleic acid target regions in a target RNA, and inhibit translation, processing, transport, or binding by proteins or riboproteins. Target regions include, and are limited to a poly-A tail, and exclude, AUG, 5' non-translated sequences, translation initiation factor binding sites, ribosome subunit binding sites, Shine Dalgarno sequence, 3' nontranslated sequences, poly- addition site, 3' cleavage site, coding region, intron, intron branch site, intron/exon junction, and splice sequence.
Ahead of Eldecalcitol treatment, this group has taken Alfacaocidol before. Eldecalcitol: the commercial name is Edirol We prescribe Edirol 0.5 or 0.75ug per day into each patient.